PRRT retreatment may be well tolerated and confer a survival benefit in patients with well-differentiated, metastatic neuroendocrine tumors, a study suggests.

Dr. Pamela L. Kunz sat down for an interview with CURE to discuss resources and ongoing initiatives that may help patients with this disease. In observation of Neuroendocrine Tumors (NETs) Awareness ...

Cedars-Sinai investigators, leading a multi-institutional team, have developed and validated a tool to predict which patients ...

Please provide your email address to receive an email when new articles are posted on . Researchers reported reductions in risk for disease progression or death with cabozantinib vs. placebo for both ...

Financial Distress Screening and Financial Navigation Among Adolescents and Young Adults Within the National Cancer Institute Community Oncology Research Program: Results of the 2022 Landscape Survey ...

Adding the somatostatin analog lanreotide to the mTOR inhibitor everolimus significantly prolonged progression-free survival in patients with unresectable or recurrent gastroenteropancreatic ...

Initiation of trial marks milestone for Crinetics’ novel nonpeptide drug conjugate platformSAN DIEGO, Dec. 03, 2025 (GLOBE ...

Cabozantinib significantly delayed disease progression in advanced pancreatic and extra-pancreatic neuroendocrine tumors, as shown in the phase 3 CABINET trial. The trial demonstrated a median PFS of ...

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine tumors. The U.S. Food and Drug Administration (FDA) has approved Cabometyx ...

Pheochromocytoma and paraganglioma (PPGL) are rare, hard-to-treat neuroendocrine tumors that form in the adrenal glands or in the extra-adrenal paraganglia Study found belzutifan shrank tumors and ...